Certain factors may increase the risk of developing OHSS, including a young age, a high ovarian reserve, polycystic ovary syndrome (PCOS), and a history of OHSS in previous fertility treatments. Additionally, the use of certain fertility medications and a robust response to ovarian stimulation can also increase the likelihood of developing OHSS. At Ferty9 Fertility Centre, our experienced fertility specialists will assess your risk factors and adjust your treatment plan accordingly to minimise the risk of OHSS.

OHSS is relatively uncommon, occurring in approximately 1-10% of women undergoing fertility treatments, particularly IVF. However, the risk can vary depending on individual factors and the specific fertility protocol. At Ferty9 Fertility Centre, we employ personalised treatment plans and closely monitor our patients to minimise the risk of OHSS and ensure optimal outcomes.

The leading cause of OHSS is the excessive use of fertility medications that activate the ovaries to produce multiple eggs. The excess production of eggs can lead to ovarian enlargement and the release of substances that cause blood vessels to seep fluid into the abdomen. Certain risk factors, such as a young age, polycystic ovary syndrome (PCOS), and a high ovarian reserve, may increase the likelihood of developing OHSS. Our experienced fertility specialists at Ferty9 Fertility Centre carefully monitor the response to fertility medications to minimise the risk of OHSS.

Ovarian hyperstimulation syndrome (OHSS) is a potentially serious aftermath that can occur during fertility treatments, such as in ovarian stimulation for in vitro fertilisation (IVF). In this condition, ovaries respond excessively to fertility medications, causing fluid buildup in the abdominal cavity and, in severe instances, the chest cavity. OHSS symptoms range from mild to severe and can cause discomfort, pain, abdominal manifestations, rapid weight gain, and, in rare cases, life-threatening complications. At Ferty9 Fertility Centre, we follow mild stimulation protocol to prioritise the safety and well-being of our patients and closely monitor the development of OHSS during fertility treatments.